Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine in MDD with comorbid GAD
NCT04220996Phase 4Completed
- Sponsor
- Lundbeck
- Start
- Dec 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 4 trial of vortioxetine in major depressive disorder (MDD), sponsored by Lundbeck. Started Dec 2019; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04220996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04220996.